Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

被引：0
|
作者：
Lim, Sung Won
Park, Song Ee
Cho, Jangho
Kim, Youjin
Lee, Hansang
Hong, Juhyun
Jeon, Eunseok
Choi, Jinoh
Lee, Gayeon
Kim, Byungjun
Min, Ju Hong
Kim, Jung Sun
Lee, Jung Eun
Choi, Joon Young
Park, Silvia
Kim, Seok Jin
Jang, Jun Ho
Kim, Won Seog
Jung, Chul Won
Kim, Kihyun
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3114
引用
收藏
页数：3
相关论文
共 50 条
  • [41] EFFICACY OF THALIDOMIDE-BASED AND BORTEZOMIB-BASED REGIMENS IN THE FIRST RELAPSE OF 146 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
    Krejci, M.
    Adam, Z.
    Krivanova, A.
    Pour, L.
    Zahradova, L.
    Mayer, J.
    Vorlicek, J.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 575 - 575
  • [42] EFFICACY OF LENALIDOMIDE-BASED AND BORTEZOMIB-BASED REGIMENS IN THE FIRST RELAPSE OF 144 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
    Krejci, M.
    Adam, Z.
    Pour, L.
    Krivanova, A.
    Sevcikova, E.
    Pelcova, J.
    Mayer, J.
    HAEMATOLOGICA, 2014, 99 : 638 - 638
  • [43] Evaluating the Efficacy and Safety of Limiting Dexamethasone in Newly Diagnosed AL Amyloidosis Compared to Conventional Dosing
    Hanna, John
    Brown, Ryan
    Burney, Zain Ali
    Abdallah, Kawther
    Mazzoni, Sandra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S208 - S208
  • [44] Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma
    Barth, Peter
    Giri, Smith
    Reagan, John L.
    Olszewski, Adam J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (01) : 14 - 22
  • [45] Bortezomib-based regimens for primary multiple myeloma patients in China: from 2006 to 2018
    He, J.
    He, D.
    Han, X.
    Zheng, G.
    Wei, G.
    Zhao, Y.
    Yang, Y.
    Wu, W.
    Huang, H.
    Cai, Z.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1904 - 1904
  • [46] Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma
    Zhou, Xin
    Wang, Jing
    Xia, Jun
    Cheng, Feng
    Mao, Jingjue
    Zhu, Jianwei
    Guo, Hongfeng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 : S5 - S5
  • [47] Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT
    Reece, Donna E.
    Rodriguez, Giovanni Piza
    Belch, Andrew
    Szwajcer, David
    Kovacs, Michael J.
    Shustik, Chaim
    Bahlis, Nizar J.
    White, Darrell J.
    Pantoja, Mariela
    Chen, Christine
    Kukreti, Vishal
    Anglin, Peter
    Trudel, Suzanne
    BLOOD, 2010, 116 (21) : 822 - 822
  • [48] Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL)
    Maramattom, Leena Varkey
    Singh, Veerpal
    Cornell, Robert Frank
    Randhawa, Jasleen K.
    Thomas, Mathew
    Saad, Ayman A.
    Palmer, Jeanne
    Hari, Parameswaran
    BLOOD, 2011, 118 (21) : 821 - 821
  • [49] BORTEZOMIB-BASED REGIMENS USED AS INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS ELIGIBLE FOR STEM CELL TRANSPLANTATION (SCT)THE COST-UTILITY ANALYSIS
    Mucha, J.
    Walczak, J.
    Tronczynski, K.
    Skrzekowska-Baran, I
    VALUE IN HEALTH, 2014, 17 (03) : A229 - A229
  • [50] Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis
    Kastritis, Efstathios
    Wechalekar, Ashutosh D.
    Dimopoulos, Meletios A.
    Merlini, Giampaolo
    Hawkins, Philip N.
    Perfetti, Vittorio
    Gillmore, Julian D.
    Palladini, Giovanni
    BLOOD, 2008, 112 (11) : 321 - 321
12345